Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2017 (2017), Article ID 8385961, 20 pages
https://doi.org/10.1155/2017/8385961
Review Article

Sterile Neuroinflammation and Strategies for Therapeutic Intervention

1Cerebrovascular Research, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
2Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
3Department of Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

Correspondence should be addressed to Manoj Banjara and Chaitali Ghosh

Received 16 September 2016; Accepted 13 December 2016; Published 3 January 2017

Academic Editor: David A. Hart

Copyright © 2017 Manoj Banjara and Chaitali Ghosh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Fernandes-Alnemri, J.-W. Yu, P. Datta, J. Wu, and E. S. Alnemri, “AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA,” Nature, vol. 458, no. 7237, pp. 509–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Lyman, D. G. Lloyd, X. Ji, M. P. Vizcaychipi, and D. Ma, “Neuroinflammation: the role and consequences,” Neuroscience Research, vol. 79, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. H. E. de Vries, M. C. Blom-Roosemalen, M. van Oosten et al., “The influence of cytokines on the integrity of the blood-brain barrier in vitro,” Journal of Neuroimmunology, vol. 64, no. 1, pp. 37–43, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kitazawa, S. Oddo, T. R. Yamasaki, K. N. Green, and F. M. LaFerla, “Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease,” The Journal of Neuroscience, vol. 25, no. 39, pp. 8843–8853, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. T. Heneka, M. P. Kummer, and E. Latz, “Innate immune activation in neurodegenerative disease,” Nature Reviews Immunology, vol. 14, no. 7, pp. 463–477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. R. M. Ransohoff, “How neuroinflammation contributes to neurodegeneration,” Science, vol. 353, no. 6301, pp. 777–783, 2016. View at Publisher · View at Google Scholar
  7. W. J. Streit, R. E. Mrak, and W. S. T. Griffin, “Microglia and neuroinflammation: a pathological perspective,” Journal of Neuroinflammation, vol. 1, article no. 14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Woodcock and M. C. Morganti-Kossmann, “The role of markers of inflammation in traumatic brain injury,” Frontiers in Neurology, vol. 4, 2013. View at Publisher · View at Google Scholar
  9. K. Kamm, W. Vanderkolk, C. Lawrence, M. Jonker, and A. T. Davis, “The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat,” The Journal of Trauma, vol. 60, no. 1, pp. 152–157, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Krueger, “The role of cytokines in sleep regulation,” Current Pharmaceutical Design, vol. 14, no. 32, pp. 3408–3416, 2008. View at Publisher · View at Google Scholar
  11. G. W. Hergenroeder, A. N. Moore, J. P. McCoy et al., “Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury,” Journal of Neuroinflammation, vol. 7, article no. 19, 2010. View at Publisher · View at Google Scholar
  12. T. Frugier, M. C. Morganti-Kossmann, D. O'Reilly, and C. A. McLean, “In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury,” Journal of Neurotrauma, vol. 27, no. 3, pp. 497–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Vezzani, “Epilepsy and inflammation in the brain: overview and pathophysiology,” Epilepsy Currents, vol. 14, no. 2, pp. 3–7, 2014. View at Publisher · View at Google Scholar
  14. M. G. De Simoni, C. Perego, T. Ravizza et al., “Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus,” European Journal of Neuroscience, vol. 12, no. 7, pp. 2623–2633, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Gorter, E. A. Van Vliet, E. Aronica et al., “Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy,” Journal of Neuroscience, vol. 26, no. 43, pp. 11083–11110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Ravizza and A. Vezzani, “Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system,” Neuroscience, vol. 137, no. 1, pp. 301–308, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. N. P. Turrin and S. Rivest, “Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy,” Neurobiology of Disease, vol. 16, no. 2, pp. 321–334, 2004. View at Publisher · View at Google Scholar
  18. A. Vezzani, J. French, T. Bartfai, and T. Z. Baram, “The role of inflammation in epilepsy,” Nature Reviews Neurology, vol. 7, no. 1, pp. 31–40, 2011. View at Publisher · View at Google Scholar
  19. J. L. Jankowsky and P. H. Patterson, “The role of cytokines and growth factors in seizures and their sequelae,” Progress in Neurobiology, vol. 63, no. 2, pp. 125–149, 2001. View at Publisher · View at Google Scholar
  20. M. Maroso, S. Balosso, T. Ravizza et al., “Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures,” Nature Medicine, vol. 16, no. 4, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Liang, Z. Lei, H. Zhang, Z. Xu, Q. Cui, and Z. C. Xu, “Toll-like receptor 4 is associated with seizures following ischemia with hyperglycemia,” Brain Research, vol. 1590, pp. 75–84, 2014. View at Publisher · View at Google Scholar
  22. S. M. Allan, P. J. Tyrrell, and N. J. Rothwell, “Interleukin-1 and neuronal injury,” Nature Reviews Immunology, vol. 5, no. 8, pp. 629–640, 2005. View at Publisher · View at Google Scholar
  23. E. A. Van Vliet, S. D. C. Araújo, S. Redeker, R. Van Schaik, E. Aronica, and J. A. Gorter, “Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy,” Brain, vol. 130, no. 2, pp. 521–534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Oby and D. Janigro, “The blood-brain barrier and epilepsy,” Epilepsia, vol. 47, no. 11, pp. 1761–1774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Ravizza, B. Gagliardi, F. Noé, K. Boer, E. Aronica, and A. Vezzani, “Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy,” Neurobiology of Disease, vol. 29, no. 1, pp. 142–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Boer, F. Jansen, M. Nellist et al., “Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex,” Epilepsy Research, vol. 78, no. 1, pp. 7–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Iyer, E. Zurolo, W. G. M. Spliet et al., “Evaluation of the innate and adaptive immunity in type i and type II focal cortical dysplasias,” Epilepsia, vol. 51, no. 9, pp. 1763–1773, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Zurolo, A. Iyer, M. Maroso et al., “Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development,” Brain, vol. 134, no. 4, pp. 1015–1032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Ravizza, K. Boer, S. Redeker et al., “The IL-1β system in epilepsy-associated malformations of cortical development,” Neurobiology of Disease, vol. 24, no. 1, pp. 128–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Gelderblom, C. G. Sobey, C. Kleinschnitz, and T. Magnus, “Danger signals in stroke,” Ageing Research Reviews, vol. 24, pp. 77–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Gelderblom, F. Leypoldt, K. Steinbach et al., “Temporal and spatial dynamics of cerebral immune cell accumulation in stroke,” Stroke, vol. 40, no. 5, pp. 1849–1857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Kleinschnitz, P. Kraft, A. Dreykluft et al., “Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature,” Blood, vol. 121, no. 4, pp. 679–691, 2013. View at Publisher · View at Google Scholar
  33. K. Hayakawa, J. Qiu, and E. H. Lo, “Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke,” Annals of the New York Academy of Sciences, vol. 1207, no. 1, pp. 50–57, 2010. View at Publisher · View at Google Scholar
  34. K. A. Jones and C. Thomsen, “The role of the innate immune system in psychiatric disorders,” Molecular and Cellular Neuroscience, vol. 53, pp. 52–62, 2013. View at Publisher · View at Google Scholar
  35. M. G. Frank, M. D. Weber, L. R. Watkins, and S. F. Maier, “Stress-induced neuroinflammatory priming: a liability factor in the etiology of psychiatric disorders,” Neurobiology of Stress, vol. 4, pp. 62–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Albus, “Psychological and social factors in coronary heart disease,” Annals of Medicine, vol. 42, no. 7, pp. 487–494, 2010. View at Publisher · View at Google Scholar
  37. R. A. Sansone and L. A. Sansone, “Depression and cardiovascular disease: just an urban legend?” Psychiatry, vol. 5, no. 11, pp. 45–48, 2008. View at Google Scholar
  38. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar
  39. J. D. Johnson, J. Campisi, C. M. Sharkey et al., “Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines,” Neuroscience, vol. 135, no. 4, pp. 1295–1307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. D. Weber, M. G. Frank, J. L. Sobesky, L. R. Watkins, and S. F. Maier, “Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge,” Brain, Behavior, and Immunity, vol. 32, pp. 112–121, 2013. View at Publisher · View at Google Scholar
  41. H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. F. E. McAlpine, J.-K. Lee, A. S. Harms et al., “Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology,” Neurobiology of Disease, vol. 34, no. 1, pp. 163–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, “Does neuroinflammation fan the flame in neurodegenerative diseases?” Molecular Neurodegeneration, vol. 4, no. 1, article no. 47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. W. F. Stewart, C. Kawas, M. Corrada, and E. J. Metter, “Risk of Alzheimer's disease and duration of NSAID use,” Neurology, vol. 48, no. 3, pp. 626–632, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Akiyama, T. Arai, H. Kondo, E. Tanno, C. Haga, and K. Ikeda, “Cell mediators of inflammation in the Alzheimer disease brain,” Alzheimer Disease and Associated Disorders, vol. 14, no. 1, pp. S47–S53, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Buchanan, M. Hutchinson, L. R. Watkins, and H. Yin, “Toll-like receptor 4 in CNS pathologies,” Journal of Neurochemistry, vol. 114, no. 1, pp. 13–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. I. Litvan, G. Halliday, M. Hallett et al., “The etiopathogenesis of Parkinson disease and suggestions for future research. Part I,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 4, pp. 251–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. B. Banati, S. E. Daniel, and S. B. Blunt, “Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease,” Movement Disorders, vol. 13, no. 2, pp. 221–227, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Gerhard, N. Pavese, G. Hotton et al., “In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease,” Neurobiology of Disease, vol. 21, no. 2, pp. 404–412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. E. MacDonald, C. M. Ambrose, M. P. Duyao et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes,” Cell, vol. 72, no. 6, pp. 971–983, 1993. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Hodges, A. D. Strand, A. K. Aragaki et al., “Regional and cellular gene expression changes in human Huntington's disease brain,” Human Molecular Genetics, vol. 15, no. 6, pp. 965–977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Crotti, C. Benner, B. E. Kerman et al., “Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors,” Nature Neuroscience, vol. 17, no. 4, pp. 513–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Crotti and C. K. Glass, “The choreography of neuroinflammation in Huntington's disease,” Trends in Immunology, vol. 36, no. 6, pp. 364–373, 2015. View at Publisher · View at Google Scholar
  54. J. S. Henkel, J. I. Engelhardt, L. Siklós et al., “Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue,” Annals of Neurology, vol. 55, no. 2, pp. 221–235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Kawamata, H. Akiyama, T. Yamada, and P. L. McGeer, “Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue,” The American Journal of Pathology, vol. 140, no. 3, pp. 691–707, 1992. View at Google Scholar · View at Scopus
  56. P. Weydt, E. C. Yuen, B. R. Ransom, and T. Möller, “Increased cytotoxic potential of microglia from ALS-transgenic mice,” GLIA, vol. 48, no. 2, pp. 179–182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. M. V. Covey, D. Loporchio, K. D. Buono, and S. W. Levison, “Opposite effect of inflammation on subventricular zone versus hippocampal precursors in brain injury,” Annals of Neurology, vol. 70, no. 4, pp. 616–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Wang and K. Jin, “Current perspectives on the link between neuroinflammation and neurogenesis,” Metabolic Brain Disease, vol. 30, no. 2, pp. 355–365, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Kettenmann, U.-K. Hanisch, M. Noda, and A. Verkhratsky, “Physiology of microglia,” Physiological Reviews, vol. 91, no. 2, pp. 461–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Ji, G. Akgul, L. P. Wollmuth, and S. E. Tsirka, “Microglia actively regulate the number of functional synapses,” PLoS ONE, vol. 8, no. 2, Article ID e56293, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Liu and J.-S. Hong, “Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Lukovic, M. Stojkovic, V. Moreno-Manzano et al., “Concise review: reactive astrocytes and stem cells in spinal cord injury: good guys or bad guys?” Stem Cells, vol. 33, no. 4, pp. 1036–1041, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Mattotti, Z. Alvarez, J. A. Ortega, J. A. Planell, E. Engel, and S. Alcántara, “Inducing functional radial glia-like progenitors from cortical astrocyte cultures using micropatterned PMMA,” Biomaterials, vol. 33, no. 6, pp. 1759–1770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Kipp, A. Norkute, S. Johann et al., “Brain-region-specific astroglial responses in vitro after LPS exposure,” Journal of Molecular Neuroscience, vol. 35, no. 2, pp. 235–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Liu, Z. Wu, Y. Hayashi, and H. Nakanishi, “Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation,” Neuroscience, vol. 216, pp. 133–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Xing, A. D. Bachstetter, and L. J. Van Eldik, “Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα,” Molecular Neurodegeneration, vol. 6, no. 1, article no. 84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. N. J. Abbott, L. Rönnbäck, and E. Hansson, “Astrocyte-endothelial interactions at the blood-brain barrier,” Nature Reviews Neuroscience, vol. 7, no. 1, pp. 41–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. E. G. Gutierrez, W. A. Banks, and A. J. Kastin, “Murine tumor necrosis factor alpha is transported from blood to brain in the mouse,” Journal of Neuroimmunology, vol. 47, no. 2, pp. 169–176, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. B. Engelhardt, “T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments,” Clinical and Experimental Neuroimmunology, vol. 1, no. 2, pp. 79–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Schwaninger, S. Sallmann, N. Petersen et al., “Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-κB,” Journal of Neurochemistry, vol. 73, no. 4, pp. 1461–1466, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Terrando, L. I. Eriksson, J. Kyu Ryu et al., “Resolving postoperative neuroinflammation and cognitive decline,” Annals of Neurology, vol. 70, no. 6, pp. 986–995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Wong, K. Dorovini-Zis, and S. R. Vincent, “Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood–brain barrier,” Experimental Neurology, vol. 190, no. 2, pp. 446–455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Fung, M. Vizcaychipi, D. Lloyd, Y. Wan, and D. Ma, “Central nervous system inflammation in disease related conditions: mechanistic prospects,” Brain Research, vol. 1446, pp. 144–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Nathan, “Points of control in inflammation,” Nature, vol. 420, no. 6917, pp. 846–852, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. B. Lee, A. Nagai, and S. U. Kim, “Cytokines, chemokines, and cytokine receptors in human microglia,” Journal of Neuroscience Research, vol. 69, no. 1, pp. 94–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Pitossi, A. Del Rey, A. Kabiersch, and H. Besedovsky, “Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice,” Journal of Neuroscience Research, vol. 48, no. 4, pp. 287–298, 1997. View at Publisher · View at Google Scholar · View at Scopus
  77. W. Sheng, Y. Zong, A. Mohammad et al., “Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1/2, iNOS and sPLA2-IIA expression in astrocytes and microglia,” Journal of Neuroinflammation, vol. 8, article 121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. Y.-K. Kim, K.-S. Na, A.-M. Myint, and B. E. Leonard, “The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 64, pp. 277–284, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Banjara, “Lipocalin-2: a new regulator of non-pathogen-associated neuroinflammation,” International Journal of Clinical and Experimental Neurology, vol. 2, no. 1, pp. 8–15, 2014. View at Google Scholar
  80. M. Banjara, Lipocalin-2 Expression in Neuroinflammatory Models: Observations and Mechanisms of Its Expression, Texas Tech University Health Sciences Center, Amarillo, Tex, USA, 2014.
  81. O. Le Thuc, N. Blondeau, J.-L. Nahon, and C. Rovère, “The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects,” Annals of the New York Academy of Sciences, vol. 1351, no. 1, pp. 127–140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Banisadr, F. Quéraud-Lesaux, M. C. Boutterin et al., “Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain,” Journal of Neurochemistry, vol. 81, no. 2, pp. 257–269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Van der Meer, A. M. Ulrich, F. Gonalez-Scarano, and E. Lavi, “Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia,” Experimental and Molecular Pathology, vol. 69, no. 3, pp. 192–201, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. A. E. Cardona, M. Li, L. Liu, C. Savarin, and R. M. Ransohoff, “Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 587–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. W. Rostène, M.-A. Dansereau, D. Godefroy et al., “Neurochemokines: a menage a trois providing new insights on the functions of chemokines in the central nervous system,” Journal of Neurochemistry, vol. 118, no. 5, pp. 680–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Guyon, G. Banisadr, C. Rovère et al., “Complex effects of stromal cell-derived factor-1α on melanin-concentrating hormone neuron excitability,” European Journal of Neuroscience, vol. 21, no. 3, pp. 701–710, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. A. M. Piccinini and K. S. Midwood, “DAMPening inflammation by modulating TLR signalling,” Mediators of Inflammation, vol. 2010, Article ID 672395, 21 pages, 2010. View at Publisher · View at Google Scholar
  88. J.-B. Kim, J. S. Choi, Y.-M. Yu et al., “HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain,” Journal of Neuroscience, vol. 26, no. 24, pp. 6413–6421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. J.-B. Kim, C.-M. Lim, Y.-M. Yu, and J.-K. Lee, “Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain,” Journal of Neuroscience Research, vol. 86, no. 5, pp. 1125–1131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. K. N. Corps, T. L. Roth, and D. B. McGavern, “Inflammation and neuroprotection in traumatic brain injury,” JAMA Neurology, vol. 72, no. 3, pp. 355–362, 2015. View at Publisher · View at Google Scholar
  91. J. Y. Zou, F. T. Crews, and M. L. Block, “Release of neuronal HMGB1 by ethanol through decreased HDAC activity activates brain neuroimmune signaling,” PLoS ONE, vol. 9, no. 2, Article ID e87915, 2014. View at Publisher · View at Google Scholar
  92. M. D. Weber, M. G. Frank, K. J. Tracey, L. R. Watkins, and S. F. Maier, “Stress induces the danger-associated molecular pattern HMGB-1 in the hippocampus of male Sprague Dawley rats: a priming stimulus of microglia and the NLRP3 inflammasome,” The Journal of Neuroscience, vol. 35, no. 1, pp. 316–324, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. K. Takata, Y. Kitamura, D. Tsuchiya, T. Kawasaki, T. Taniguchi, and S. Shimohama, “High mobility group box protein-1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity,” Journal of Neuroscience Research, vol. 78, no. 6, pp. 880–891, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Thundyil and K. Lim, “DAMPs and neurodegeneration,” Ageing Research Reviews, vol. 24, part A, pp. 17–28, 2015. View at Publisher · View at Google Scholar
  95. P. Fang, M. Schachner, and Y. Shen, “HMGB1 in development and diseases of the central nervous system,” Molecular Neurobiology, vol. 45, no. 3, pp. 499–506, 2012. View at Publisher · View at Google Scholar
  96. H. Gao, H. Zhou, F. Zhang, B. C. Wilson, W. Kam, and J. Hong, “HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration,” Journal of Neuroscience, vol. 31, no. 3, pp. 1081–1092, 2011. View at Publisher · View at Google Scholar
  97. J. Zhang, N. Niu, M. Wang et al., “Neuron-derived IgG protects dopaminergic neurons from insult by 6-OHDA and activates microglia through the FcγR i and TLR4 pathways,” The International Journal of Biochemistry & Cell Biology, vol. 45, no. 8, pp. 1911–1920, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. E. K. Lindersson, P. Højrup, W. P. Gai, D. Locker, D. Martin, and P. H. Jensen, “α-synuclein filaments bind the transcriptional regulator HMGB-1,” NeuroReport, vol. 15, no. 18, pp. 2735–2739, 2004. View at Google Scholar · View at Scopus
  99. H. J. Min, E. A. Ko, J. Wu et al., “Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates,” The Journal of Immunology, vol. 190, no. 4, pp. 1797–1806, 2013. View at Publisher · View at Google Scholar
  100. J. S. Park, J. Arcaroli, H.-K. Yum et al., “Activation of gene expression in human neutrophils by high mobility group box 1 protein,” American Journal of Physiology—Cell Physiology, vol. 284, no. 4, pp. C870–C879, 2003. View at Publisher · View at Google Scholar
  101. A. Taguchi, D. C. Blood, G. del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Broere, R. van der Zee, and W. van Eden, “Heat shock proteins are no DAMPs, rather ‘DAMPERs’,” Nature Reviews Immunology, vol. 11, no. 8, article 565, 2011. View at Publisher · View at Google Scholar
  103. M. T. Ganter, L. B. Ware, M. Howard et al., “Extracellular heat shock protein 72 is a marker of the stress protein response in acute lung injury,” AJP: Lung Cellular and Molecular Physiology, vol. 291, no. 3, pp. L354–L361, 2006. View at Publisher · View at Google Scholar
  104. H. Adachi, M. Katsuno, M. Waza, M. Minamiyama, F. Tanaka, and G. Sobue, “Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications,” International Journal of Hyperthermia, vol. 25, no. 8, pp. 647–654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Asea, “Heat shock proteins and toll-like receptors,” in Toll-Like Receptors (TLRs) and Innate Immunity, vol. 183 of Handbook of Experimental Pharmacology, pp. 111–127, Springer, Berlin, Germany, 2008. View at Publisher · View at Google Scholar
  106. K. Rosenberger, P. Dembny, K. Derkow et al., “Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathway,” Molecular Neurodegeneration, vol. 10, article no. 5, 2015. View at Publisher · View at Google Scholar
  107. J. Qi, Y. Liu, P. Yang et al., “Heat shock protein 90 inhibition by 17-Dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke,” American Journal of Translational Research, vol. 7, no. 10, pp. 1826–1837, 2015. View at Google Scholar
  108. N. Kim, J. Y. Kim, and M. A. Yenari, “Pharmacological induction of the 70-kDa heat shock protein protects against brain injury,” Neuroscience, vol. 284, pp. 912–919, 2015. View at Publisher · View at Google Scholar
  109. J. Y. Kim, M. A. Yenari, and J. E. Lee, “Regulation of inflammatory transcription factors by heat shock protein 70 in primary cultured astrocytes exposed to oxygen-glucose deprivation,” Neuroscience, vol. 286, pp. 272–280, 2015. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Shiber and T. Ravid, “Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome,” Biomolecules, vol. 4, no. 3, pp. 704–724, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Marino Gammazza, R. Colangeli, G. Orban et al., “Hsp60 response in experimental and human temporal lobe epilepsy,” Scientific Reports, vol. 5, article 9434, 2015. View at Publisher · View at Google Scholar
  112. L. J. Van Eldik and M. S. Wainwright, “The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain,” Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp. 97–108, 2003. View at Google Scholar · View at Scopus
  113. G. Sorci, R. Bianchi, F. Riuzzi et al., “S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond,” Cardiovascular Psychiatry and Neurology, vol. 2010, Article ID 656481, 13 pages, 2010. View at Publisher · View at Google Scholar
  114. L. J. Van Eldik and W. S. T. Griffin, “S100β expression in Alzheimer's disease: relation to neuropathology in brain regions,” Biochimica et Biophysica Acta, vol. 1223, no. 3, pp. 398–403, 1994. View at Publisher · View at Google Scholar · View at Scopus
  115. M. L. Chaves, A. L. Camozzato, E. D. Ferreira et al., “Serum levels of S100B and NSE proteins in Alzheimer's disease patients,” Journal of Neuroinflammation, vol. 7, article 6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. G. Esposito, C. Scuderi, J. Lu et al., “S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 914–927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. T. Mori, T. Town, J. Tan et al., “Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 2, pp. 571–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Sathe, W. Maetzler, J. D. Lang et al., “S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway,” Brain, vol. 135, no. 11, pp. 3336–3347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Kim, H. J. Waldvogel, R. L. M. Faull, M. A. Curtis, and L. F. B. Nicholson, “The RAGE receptor and its ligands are highly expressed in astrocytes in a grade-dependant manner in the striatum and subependymal layer in Huntington's disease,” Journal of Neurochemistry, vol. 134, no. 5, pp. 927–942, 2015. View at Publisher · View at Google Scholar · View at Scopus
  120. M. E. Choudhury, T. Moritoyo, M. Kubo et al., “Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity,” Brain Research, vol. 1384, pp. 170–178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Freund, B. Bloom, J. Bokobza et al., “Predictive value of S100-B and copeptin for outcomes following seizure: the BISTRO international cohort study,” PLoS ONE, vol. 10, no. 4, Article ID e0122405, 2015. View at Publisher · View at Google Scholar
  122. S. V. Kabadi, B. A. Stoica, D. B. Zimmer et al., “S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury,” Journal of Cerebral Blood Flow & Metabolism, vol. 35, no. 12, pp. 2010–2020, 2015. View at Publisher · View at Google Scholar
  123. T. Falcone, D. Janigro, R. Lovell et al., “S100B blood levels and childhood trauma in adolescent inpatients,” Journal of Psychiatric Research, vol. 62, pp. 14–22, 2015. View at Publisher · View at Google Scholar
  124. N. Marchi, G. Betto, V. Fazio et al., “Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema,” Epilepsia, vol. 50, no. 4, pp. 664–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Jylhävä, M. Jylhä, T. Lehtimäki, A. Hervonen, and M. Hurme, “Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: The Vitality 90+ Study,” Experimental Gerontology, vol. 47, no. 5, pp. 372–378, 2012. View at Publisher · View at Google Scholar
  126. M. Pinti, E. Cevenini, M. Nasi et al., “Circulating mitochondrial DNA increases with age and is a familiar trait: implications for ‘inflamm-aging’,” European Journal of Immunology, vol. 44, no. 5, pp. 1552–1562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  127. Q. Zheng, “Editorial: at the crossroad between inflammation and skin aging,” Inflammation and Allergy—Drug Targets, vol. 13, no. 3, pp. 151–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. D. J. Cox, R. H. Field, D. G. Williams et al., “DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease,” Glia, vol. 63, no. 5, pp. 812–825, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Mathew, T. A. Lindsley, A. Sheridan et al., “Degraded mitochondrial dna is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration,” Journal of Alzheimer's Disease, vol. 30, no. 3, pp. 617–627, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Jylhävä, T. Nevalainen, S. Marttila, M. Jylhä, A. Hervonen, and M. Hurme, “Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty,” Aging Cell, vol. 12, no. 3, pp. 388–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. D. Communi, R. Janssens, N. Suarez-Huerta, B. Robaye, and J.-M. Boeynaems, “Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors,” Cellular Signalling, vol. 12, no. 6, pp. 351–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. P. Xu, Y. Xu, B. Hu et al., “Extracellular ATP enhances radiation-induced brain injury through microglial activation and paracrine signaling via P2X7 receptor,” Brain, Behavior, and Immunity, vol. 50, pp. 87–100, 2015. View at Publisher · View at Google Scholar
  133. H. M. Wilkins, S. M. Carl, S. G. Weber et al., “Mitochondrial lysates induce inflammation and Alzheimer's disease-relevant changes in microglial and neuronal cells,” Journal of Alzheimer's Disease, vol. 45, no. 1, pp. 305–318, 2015. View at Publisher · View at Google Scholar
  134. M. Gan, S. Moussaud, P. Jiang, and P. J. McLean, “Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction,” Neurobiology of Aging, vol. 36, no. 2, pp. 1209–1220, 2015. View at Publisher · View at Google Scholar
  135. D. Communi, B. Robaye, and J. M. Boeynaems, “Pharmacological characterization of the human P2Y11 receptor,” British Journal of Pharmacology, vol. 128, no. 6, pp. 1199–1206, 1999. View at Publisher · View at Google Scholar
  136. C. Lohr, A. Grosche, A. Reichenbach, and D. Hirnet, “Purinergic neuron-glia interactions in sensory systems,” Pflügers Archiv, vol. 466, no. 10, pp. 1859–1872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. T. Engel, M. Alves, C. Sheedy, and D. C. Henshall, “ATPergic signalling during seizures and epilepsy,” Neuropharmacology, vol. 104, pp. 140–153, 2016. View at Publisher · View at Google Scholar · View at Scopus
  138. L. Llull, S. Amaro, and Á. Chamorro, “Administration of uric acid in the emergency treatment of acute ischemic stroke,” Current Neurology and Neuroscience Reports, vol. 16, no. 1, article 4, 2016. View at Publisher · View at Google Scholar
  139. P. Auinger, K. Kieburtz, and M. P. Mcdermott, “The relationship between uric acid levels and Huntington's disease progression,” Movement Disorders, vol. 25, no. 2, pp. 224–228, 2010. View at Publisher · View at Google Scholar
  140. E. Al-Khateeb, A. Althaher, M. Al-Khateeb et al., “Relation between uric acid and Alzheimer's disease in elderly Jordanians,” Journal of Alzheimer's Disease, vol. 44, no. 3, pp. 859–865, 2015. View at Publisher · View at Google Scholar · View at Scopus
  141. R. Brouns, A. Wauters, G. Van De Vijver, D. De Surgeloose, R. Sheorajpanday, and P. P. De Deyn, “Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 3, pp. 383–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. C.-J. Chen, Y. Shi, A. Hearn et al., “MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals,” The Journal of Clinical Investigation, vol. 116, no. 8, pp. 2262–2271, 2006. View at Publisher · View at Google Scholar
  143. M. Jin, F. Yang, I. Yang et al., “Uric acid, hyperuricemia and vascular diseases,” Frontiers in Bioscience, vol. 17, no. 1, pp. 656–669, 2012. View at Publisher · View at Google Scholar
  144. R. Liu-Bryan, K. Pritzker, G. S. Firestein, and R. Terkeltaub, “TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation,” The Journal of Immunology, vol. 174, no. 8, pp. 5016–5023, 2005. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Y. Seong and P. Matzinger, “Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses,” Nature Reviews Immunology, vol. 4, no. 6, pp. 469–478, 2004. View at Publisher · View at Google Scholar
  146. M. R. Hutchinson, S. T. Bland, K. W. Johnson, K. C. Rice, S. F. Maier, and L. R. Watkins, “Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward,” TheScientificWorldJournal, vol. 7, no. 2, pp. 98–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  147. L. R. Watkins, M. R. Hutchinson, K. C. Rice, and S. F. Maier, “The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia,” Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 581–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. H. R. Wardill, Y. Z. Van Sebille, K. A. Mander et al., “Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity,” Cancer Treatment Reviews, vol. 41, no. 2, pp. 122–128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. D. S. Arroyo, J. A. Soria, E. A. Gaviglio, M. C. Rodriguez-Galan, and P. Iribarren, “Toll-like receptors are key players in neurodegeneration,” International Immunopharmacology, vol. 11, no. 10, pp. 1415–1421, 2011. View at Publisher · View at Google Scholar
  150. N. Laflamme and S. Rivest, “Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components,” The FASEB Journal, vol. 15, no. 1, pp. 155–163, 2001. View at Publisher · View at Google Scholar · View at Scopus
  151. T. Trotta, C. Porro, R. Calvello, and M. A. Panaro, “Biological role of Toll-like receptor-4 in the brain,” Journal of Neuroimmunology, vol. 268, no. 1-2, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Tahara, H.-D. Kim, J.-J. Jin, J. A. Maxwell, L. Li, and K.-I. Fukuchi, “Role of toll-like receptor signalling in Aβ uptake and clearance,” Brain, vol. 129, no. 11, pp. 3006–3019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  153. M. S. Lee and Y.-J. Kim, “Signaling pathways downstream of pattern-recognition receptors and their cross talk,” Annual Review of Biochemistry, vol. 76, pp. 447–480, 2007. View at Publisher · View at Google Scholar · View at Scopus
  154. L. A. J. O'Neill and A. G. Bowie, “The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling,” Nature Reviews Immunology, vol. 7, no. 5, pp. 353–364, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Su, F. Bai, H. Zhou, and Z. Zhang, “Reprint of: microglial toll-like receptors and Alzheimer’s disease,” Brain, Behavior, and Immunity, vol. 55, pp. 166–178, 2016. View at Publisher · View at Google Scholar
  156. T. Chavakis, A. Bierhaus, N. Al-Fakhri et al., “The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment,” The Journal of Experimental Medicine, vol. 198, no. 10, pp. 1507–1515, 2003. View at Publisher · View at Google Scholar
  157. M. Lamkanfi and V. M. Dixit, “The inflammasomes,” PLoS Pathogens, vol. 5, no. 12, Article ID e1000510, 2009. View at Publisher · View at Google Scholar
  158. L. C. Freeman and J. P. Ting, “The pathogenic role of the inflammasome in neurodegenerative diseases,” Journal of Neurochemistry, vol. 136, supplement 1, pp. 29–38, 2016. View at Publisher · View at Google Scholar
  159. J. P. de Rivero Vaccari, W. D. Dietrich, and R. W. Keane, “Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury,” Journal of Cerebral Blood Flow & Metabolism, vol. 34, no. 3, pp. 369–375, 2014. View at Publisher · View at Google Scholar
  160. A. Chorny and M. Delgado, “Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1,” The American Journal of Pathology, vol. 172, no. 5, pp. 1297–1302, 2008. View at Publisher · View at Google Scholar
  161. D. Musumeci, G. N. Roviello, and D. Montesarchio, “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies,” Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Wang, H. Liao, M. Ochani et al., “Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis,” Nature Medicine, vol. 10, no. 11, pp. 1216–1221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Zou and F. T. Crews, “Glutamate/NMDA excitotoxicity and HMGB1/TLR4 neuroimmune toxicity converge as components of neurodegeneration,” AIMS Molecular Science, vol. 2, no. 2, pp. 77–100, 2015. View at Publisher · View at Google Scholar
  164. M. Sumiyoshi, J. Satomi, K. T. Kitazato et al., “PPARγ-dependent and -independent inhibition of the HMGB1/TLR9 pathway by eicosapentaenoic acid attenuates ischemic brain damage in ovariectomized rats,” Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 6, pp. 1187–1195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. Y. Okuma, K. Liu, H. Wake et al., “Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction,” Neuropharmacology, vol. 85, pp. 18–26, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. S.-W. Kim, Y. Jin, J.-H. Shin et al., “Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion,” Neurobiology of Disease, vol. 46, no. 1, pp. 147–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  167. W. Li, J. Li, A. E. Sama, and H. Wang, “Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release,” Molecular Medicine, vol. 19, pp. 203–211, 2013. View at Publisher · View at Google Scholar
  168. W. Li, J. Li, M. Ashok et al., “A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1,” The Journal of Immunology, vol. 178, no. 6, pp. 3856–3864, 2007. View at Publisher · View at Google Scholar
  169. L. Wang, X. Zhang, L. Liu, R. Yang, L. Cui, and M. Li, “Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-κB expression,” Neuroscience Letters, vol. 471, no. 3, pp. 152–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Hidaka, H. Iwasaka, S. Hagiwara, and T. Noguchi, “Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury,” Journal of Surgical Research, vol. 165, no. 1, pp. 142–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. S. Hagiwara, H. Iwasaka, K. Togo, and T. Noguchi, “A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1,” Inflammation, vol. 31, no. 4, pp. 227–234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Hagiwara, H. Iwasaka, and T. Noguchi, “Retraction note to: nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury,” Journal of Anesthesia, vol. 29, no. 3, p. 484, 2015. View at Publisher · View at Google Scholar · View at Scopus
  173. S. H. Dave, J. S. Tilstra, K. Matsuoka et al., “Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 633–643, 2009. View at Publisher · View at Google Scholar
  174. X. Su, H. Wang, J. Zhao, H. Pan, and L. Mao, “Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-κB pathway after traumatic brain injury in the rat,” Mediators of Inflammation, vol. 2011, Article ID 807142, 10 pages, 2011. View at Publisher · View at Google Scholar
  175. H. Wang, M. F. Ward, and A. E. Sama, “Novel HMGB1-inhibiting therapeutic agents for experimental sepsis,” Shock, vol. 32, no. 4, pp. 348–357, 2009. View at Publisher · View at Google Scholar
  176. H. Yang, M. Ochani, J. Li et al., “Reversing established sepsis with antagonists of endogenous high-mobility group box 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 296–301, 2004. View at Publisher · View at Google Scholar
  177. S. Muhammad, W. Barakat, S. Stoyanov et al., “The HMGB1 receptor RAGE mediates ischemic brain damage,” The Journal of Neuroscience, vol. 28, no. 46, pp. 12023–12031, 2008. View at Publisher · View at Google Scholar
  178. D. Landsman and M. Bustin, “A signature for the HMG-1 box DNA-binding proteins,” BioEssays, vol. 15, no. 8, pp. 539–546, 1993. View at Publisher · View at Google Scholar · View at Scopus
  179. T. Sasaki, K. Liu, T. Agari et al., “Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease,” Experimental Neurology, vol. 275, part 1, pp. 220–231, 2016. View at Publisher · View at Google Scholar
  180. S. J. Webster, S. Mruthinti, W. D. Hill, J. J. Buccafusco, and A. V. Terry Jr., “An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease,” NeuroMolecular Medicine, vol. 14, no. 2, pp. 119–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  181. A. Tsung, R. Sahai, H. Tanaka et al., “The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion,” The Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135–1143, 2005. View at Publisher · View at Google Scholar
  182. M. L. D. Udan, D. Ajit, N. R. Crouse, and M. R. Nichols, “Toll-like receptors 2 and 4 mediate Aβ(1-42) activation of the innate immune response in a human monocytic cell line,” Journal of Neurochemistry, vol. 104, no. 2, pp. 524–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. T. Arumugam, V. Ramachandran, S. B. Gomez, A. M. Schmidt, and C. D. Logsdon, “S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis,” Clinical Cancer Research, vol. 18, no. 16, pp. 4356–4364, 2012. View at Publisher · View at Google Scholar
  184. R. Deane, I. Singh, A. P. Sagare et al., “A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1377–1392, 2012. View at Publisher · View at Google Scholar
  185. H. Li, J. Yu, D. Zhang et al., “Inhibition of the Receptor for Advanced Glycation End-Products (RAGE) attenuates neuroinflammation while sensitizing cortical neurons towards death in experimental subarachnoid hemorrhage,” Molecular Neurobiology, pp. 1–13, 2016. View at Publisher · View at Google Scholar
  186. R. C. Coll, A. A. Robertson, J. J. Chae et al., “A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases,” Nature Medicine, vol. 21, pp. 248–255, 2015. View at Publisher · View at Google Scholar
  187. N. Marchi, T. Granata, E. Freri et al., “Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics,” PLOS ONE, vol. 6, no. 3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. A. Rolls, R. Shechter, A. London et al., “Toll-like receptors modulate adult hippocampal neurogenesis,” Nature Cell Biology, vol. 9, no. 9, pp. 1081–1088, 2007. View at Publisher · View at Google Scholar · View at Scopus
  189. H. Capiralla, V. Vingtdeux, H. Zhao et al., “Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade,” Journal of Neurochemistry, vol. 120, no. 3, pp. 461–472, 2012. View at Publisher · View at Google Scholar
  190. S.-S. Mao, R. Hua, X.-P. Zhao et al., “Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-κB pathway,” Journal of Neurotrauma, vol. 29, no. 10, pp. 1941–1959, 2012. View at Publisher · View at Google Scholar · View at Scopus
  191. Y. Kuroiwa, Y. Takakusagi, T. Kusayanagi et al., “Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein,” PLoS ONE, vol. 8, no. 5, Article ID e63073, 2013. View at Publisher · View at Google Scholar
  192. G. Chen, S. Zhang, J. Shi, J. Ai, M. Qi, and C. Hang, “Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-κB pathway,” Experimental Neurology, vol. 216, no. 2, pp. 398–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  193. L. Wang, X. Zhang, L. Liu et al., “Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-κB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia,” Brain Research, vol. 1321, pp. 143–151, 2010. View at Publisher · View at Google Scholar
  194. H. Qiao, X. Zhang, C. Zhu et al., “Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia,” Brain Research, vol. 1448, pp. 71–81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  195. A. J. Williams, J. R. Dave, and F. C. Tortella, “Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor κB (NF-κB), inflammatory gene expression, and leukocyte infiltration,” Neurochemistry International, vol. 49, no. 2, pp. 106–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  196. J. S. Miners, S. Baig, J. Palmer, L. E. Palmer, P. G. Kehoe, and S. Love, “SYMPOSIUM: clearance of Aβ from the brain in Alzheimer's disease: Aβ-degrading enzymes in Alzheimer's disease,” Brain Pathology, vol. 18, no. 2, pp. 240–252, 2008. View at Publisher · View at Google Scholar
  197. R. D. Bell, A. P. Sagare, A. E. Friedman et al., “Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system,” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 5, pp. 909–918, 2006. View at Publisher · View at Google Scholar
  198. R. O. Weller, M. Subash, S. D. Preston, I. Mazanti, and R. O. Carare, “Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease,” Brain Pathology, vol. 18, no. 2, pp. 253–266, 2008. View at Publisher · View at Google Scholar
  199. E. N. Bakker, B. J. Bacskai, M. Arbel-Ornath et al., “Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases,” Cellular and Molecular Neurobiology, vol. 36, no. 2, pp. 181–194, 2016. View at Publisher · View at Google Scholar
  200. S. Mondragón-Rodríguez, G. Perry, J. Luna-Muñoz, M. C. Acevedo-Aquino, and S. Williams, “Phosphorylation of tau protein at sites Ser396–404 is one of the earliest events in Alzheimer's disease and Down syndrome,” Neuropathology and Applied Neurobiology, vol. 40, no. 2, pp. 121–135, 2014. View at Publisher · View at Google Scholar
  201. G. V. W. Johnson and W. H. Stoothoff, “Tau phosphorylation in neuronal cell function and dysfunction,” Journal of Cell Science, vol. 117, no. 24, pp. 5721–5729, 2004. View at Publisher · View at Google Scholar
  202. C. M. Wischik, C. R. Harrington, and J. M. Storey, “Tau-aggregation inhibitor therapy for Alzheimer's disease,” Biochemical Pharmacology, vol. 88, no. 4, pp. 529–539, 2014. View at Publisher · View at Google Scholar
  203. J. Y. Kim and M. A. Yenari, “The immune modulating properties of the heat shock proteins after brain injury,” Anatomy & Cell Biology, vol. 46, no. 1, pp. 1–7, 2013. View at Publisher · View at Google Scholar
  204. R. B. Dange, D. Agarwal, R. Teruyama, and J. Francis, “Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension,” Journal of Neuroinflammation, vol. 12, no. 1, article 31, 2015. View at Publisher · View at Google Scholar